Global NASH Council reposted this
Dr. Kenneth Cusi shares insights about the new MASLD/MASH Nomenclature. Why a Need for Increased Awareness about MASLD? * MASLD affects two out of three people with type 2 diabetes. * It increases the risk of developing cirrhosis, liver cancer and overall liver-related mortality. * Increases the risk of developing type 2 diabetes, cardiovascular disease and extrahepatic malignancies. * MASLD has a major negative impact on health-related quality of life and is a major economic burden. * MASLD is reversable with an early diagnosis and intervention Intervention encompasses a healthy lifestyle, some diabetes and obesity management pharmacotherapies, metabolic surgery and FDA-approved medications Positive Aspects of the New Nomenclature and Knowledge Gaps * The term "metabolic dysfunction" highlights the key role of insulin resistance and metabolic defects in the pathophysiology of MASLD. Knowledge gap: To examine heterogeneity of insulin resistance and metabolic factors in people with MASLD * Prediabetes and diabetes are now clearly defined as cardiometabolic risk factors for MASLD. Knowledge gap: - Better understand the role of prediabetes - Establish the role of different diabetes types (e.g., T1D) and novel endotypes EASL | The Home of Hepatology Global Liver Institute Global NASH Council European Liver Patients' Association - ELPA Mazen Noureddin, MD, MHSc Naim Alkhouri, MD, FAASLD Global NASH Council James Kim
